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ABSTRACT 
Nicotinamide N-methyltransferase (NNMT) is one of the most abundant small molecule 
methyltransferases in the human body and is primarily responsible for the N-methylation of the 
nicotinamide (vitamin B3). Employing the cofactor S-adenosyl-L-methionine (AdoMet), NNMT 
transfers a methyl group to the pyridine nitrogen of nicotinamide to generate N-methyl 
nicotinamde (NMA). Interestingly, NNMT is also able to N-methylate a variety of other 
pyridine-containing small molecules suggesting a secondary role for the enzyme in the 
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detoxification of xenobiotics. A number of recent studies have also revealed links between 
NNMT overexpression and a variety of diseases including multiple cancers, Parkinson’s disease, 
diabetes, and obesity. To facilitate further study of both the substrate scope and potential for 
inhibitor development, we here describe the development of a new NNMT activity assay. The 
assay makes use of ultra-high performance hydrophilic interaction chromatography (UHP-
HILIC) allowing for rapid separation of the reaction products, coupled with quadrupole-time-of-
flight mass spectrometric (QTOF-MS) detection, providing for high sensitivity and permitting 
the analysis of small samples. We successfully demonstrated the robustness of the method by 
performing kinetic analyses of NNMT-mediated methylation for a range of pyridine-based 
substrates. These findings also provide new insight into the diversity of substrate recognition by 
NNMT in a quantitative manner. In addition, we further established the applicability of the assay 
in the characterization of small molecule inhibitors of NNMT. To do so we investigated the 
inhibition of NNMT by the nonspecific methyltransferase inhibitors sinefungin and S-adenosyl-
L-homocysteine revealing IC50 values in the low micromolar range. The results of these 
inhibition studies are particularly noteworthy as they will enable future efforts toward the 
development of new NNMT-specific inhibitors. 
 
INTRODUCTION 
The methyltransferases are a class of enzymes that methylate DNA, RNA, proteins, and small 
molecules using nature’s general methyl donor S-adenosyl-L-methionine (AdoMet) as a cofactor. 
Protein methyltransferases have gained much attention in recent years given their roles in the 
post-translational modification of many epigenetic targets implicated in gene expression. By 
comparison, the non-protein methyltransferases (NPMTs) have generally received less attention. 
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NPMTs represent group of methyltransferases that methylate various small molecules that are 
typically involved in metabolic pathways, signal transduction, and the biosynthesis or 
modification/detoxification of bioactive molecules.1 One such NPMT is nicotinamide N-
methyltransferase (NNMT, EC 2.1.1.1), which catalyses the N-methylation of nicotinamide (NA) 
using AdoMet to form N’-methylnicotinamide (MNA) and S-adenosyl-L-homocysteine 
(AdoHcy) as depicted in figure 1. In addition to nicotinamide, previous reports using NNMT 
isolated from porcine liver found that the enzyme is also able to methylate a range of other 
pyridine-containing compounds.2 In the human body NNMT is expressed mainly in the liver, but 
has been found in lower levels in other organs as well.3,4 NNMT’s primary role in the liver has 
traditionally been viewed as serving various detoxification and metabolic pathways.5 Recently, 
however, additional roles have also been attributed to NNMT indicating involvement in a range 
of disease states and physiological processes including Parkinson’s disease, numerous cancers, 
metabolic disorders, obesity, and lifespan regulation.6–12 The growing body of knowledge 
implicating NNMT in both healthy and disease states also suggests that the enzyme might be an 
interesting therapeutic target. Facilitating the design of new NNMT inhibitors is the recently 
Figure 1. Methylation of nicotinamide by S-adenosyl-L-
methionine (AdoMet) catalysed by nicotinamide N-
methyltransferase (NNMT), forming N’-methyl-
nicotinamide (MNA) and S-adenosyl-L-homocysteine 
(AdoHcy). 
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published crystal structure of NNMT which provides key insights in the active site residues and 
their interaction with the enzyme’s substrates.13 Also crucial to the development of inhibitors is a 
reliable and efficient assay method for quantifying NNMT’s methylation activity towards 
nicotinamide and the various other substrates that have been identified and proposed to date.  
A general method for assaying methyltransferase enzymes involves measuring production of 
the AdoMet by-product AdoHcy. This approach can however, be complicated by unpredictable 
background levels of AdoHcy commonly encountered in such assays. Such background AdoHcy 
can be the result of contamination in the AdoMet used, formation of AdoHcy via 
automethylation, or by the nonenzymatic decomposition of SAM into AdoHcy.14,15 Other 
analytical methods more specific for measuring the activity of NNMT have also been developed. 
One approach is to use radiolabeled AdoMet which allows for quantification of NMNT activity 
by detecting the amount of radioactive MNA produced.2,16  As an alternative, high performance 
liquid chromatography (HPLC) coupled with UV or fluorescence-based detection can also be 
used to assess the production of MNA by NNMT.17,18 These methods however, are complicated 
by the use of complex buffer systems, tedious work-up, derivatization reactions, long run times, 
or the use of radioactive reagents.2,16–18 Radiochemical or derivatization-based methods are not 
ideally suited for measuring large numbers of samples or for screening libraries of potential 
inhibitors. Also, while a recently reported HPLC-UV method for measuring NNMT activity in 
human liver cytosol allowed for the determination of kinetic parameters of NNMT,18 the assay 
conditions used are also not optimal for screening purposes. 
In developing an alternative approach to assaying the activity of NNMT we chose to employ 
a Hydrophilic Liquid Interaction Chromatography (HILIC) separation technique coupled with a 
mass spectrometric-based system detection system. As the product(s) of the enzymatic reaction 
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catalysed by NNMT are generally methylated pyridines, the analytes of interest will be 
inherently positively charged compounds. Such polar compounds can be analysed using 
Hydrophilic Liquid Interaction Chromatography (HILIC) without the need for derivatization or 
the application of ion-pairing agents. These factors also make HILIC highly compatible with 
selective and sensitive mass spectrometric (MS) detection.19 In addition, the use of ultra-high-
performance (UHP) column material in HILIC offers greater separation efficiency, sensitivity, 
and the admissibility of higher flow rates relative to conventional C18 HPLC-based separations 
leading to significantly shorter analysis times and higher sample throughput. 
To demonstrate the applicability of our UHP-HILIC-MS method for the detection of 
methylated pyridines, a range of pyridine-containing compounds were tested as substrates for 
NNMT. A set of previously identified substrates, based upon the activity of NNMT isolated from 
porcine liver, formed the basis of our quantitative substrate recognition screen.2 This substrate 
screen was also expanded to include other physiologically relevant pyridines so as to gain further 
insight into the NNMT substrate scope. The UHP-HILIC-MS method here described shows high 
sensitivity and selectivity for the detection of methylated pyridines. It further benefits from 
convenient sample work-up and very short run-times in the analysis of pyridine-containing 
compounds as substrates for NNMT. A subset of alternate NNMT substrates for which 
methylation activity was found to be similar to that of nicotinamide were identified and the 
kinetic parameters Vmax, Km and kcat determined. Furthermore, we demonstrate that the assay can 
be readily adapted for use in screening inhibitors of NNMT as demonstrated by establishing the 
IC50 values for AdoHcy and the general methyltransferases inhibitor sinefungin. 
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EXPERIMENTAL SECTION  
Cloning, Expression, and Purification of recombinant human NNMT 
Total RNA was isolated from normal human renal tissue using the SV Total RNA Isolation Kit 
(Promega, Madison, WI, USA) as per previously described.20 Total RNA (2µg) was reverse-
transcribed into cDNA using M-MLV Reverse Transcriptase (Promega, Madison, WI, USA) and 
random primers. cDNA was then subjected to PCR using the primers 5’-
TCACATATGGAATCAGGCTTCA-3’ (forward) and 5’-CTAAAGCTTTCACAGGGGTCTG-
3’ (reverse) to amplify the human NNMT open reading frame and to insert NdeI and HindIII 
restriction sites. The amplified and digested product was then cloned into a pET-28a plasmid 
vector to obtain the expression construct pET-28a-wt-hNNMT, which was subsequently 
transformed into E. Coli BL21 (DE3). Human recombinant NNMT was isolated from IPTG-
induced cells and purified to homogeneity using nickel affinity purification as previously 
described.13 Purity was confirmed using SDS-PAGE/Coomassie blue staining and NNMT 
identity was confirmed using SDS-PAGE/Western blotting. 
Catalytic activity of recombinant protein was evaluated as previously reported, with minor 
modifications,13 with 1 U of enzyme activity representing the formation of 1 nmol of MNA per 
hour of incubation at 37 °C. Homogeneous recombinant NNMT specific activity was 6740 U/mg 
protein and 6367 U/mg protein for the two batches of NNMT used with protein concentrations of 
1.3 mg/mL and 0.94 mg/mL respectively. 
Enzymatic Activity Assay 
Enzyme activity assays were performed as previously described13 with NNMT (16.25 µg/mL, 
550 nM) in 50 mM Tris buffer (pH 8.6) containing 1 mM DTT (all final concentrations). The 
enzyme was incubated with the substrate pyridine compound for 5 minutes at 37°C using a heat 
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block before initiating the reaction by addition of AdoMet (for substrates that were not soluble in 
water, stock solutions were prepared in DMSO and diluted to a final concentration of <5% 
DMSO in the assay mixture. As a control, the methylation of nicotinamide was also measured in 
the presence of 5% DMSO revealing no difference in enzymatic activity. For these screens the 
final reagent concentrations were 100 µM AdoMet and 2.0 mM substrate and a series of time 
points were initially investigated (5, 15, 30, and 60 minutes). At each time point 15 µL aliquots 
of the reaction mixture were taken and added to 70 µL acetonitrile which served to quench the 
reaction by causing precipitation of the enzyme. Samples were then centrifuged for 5 minutes at 
3,000 rpm and the supernatant analysed.  
In cases where an increase in signal for the methylated product was observed, a second 
screen was performed in order to establish the initial velocity conditions of the particular 
substrate. For the more comprehensive screening, final reagent concentrations were 0.02, 0.05, 
0.2, 0.5, 2.0, 5.0, 20 and 50 mM substrate and 40 µM AdoMet. The time-points used were 5, 15, 
30 and 60 minutes after which 15 µL aliquots of the reaction mixture added to 70 µL acetonitrile 
(containing the relevant internal standard) and the sample worked-up as described above. For 
each of the substrates investigated in this screen the trideuteromethylated analogue was prepared 
for use as an internal standard. In addition, the non-isotope enriched methylated versions of each 
substrate were synthesized and used to confirm signal linearity. After establishing the suitable 
initial velocity conditions for each substrate the NNMT activity assay was performed in triplicate 
using a substrate concentration range of 0.02, 0.05, 0.2, 0.5, 2.0, 5.0, 20 and 50 mM and 40 µM 
AdoMet. The data thus generated was used in determining the kinetic parameters Km, Vmax and 
kcat for each substrate investigated. 
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UHP-HILIC-MS method for analysis of methylated products 
UHP-HILIC-MS analysis was performed using an 1290 Infinity UHPLC system (Agilent 
Technologies, Waldbronn, BW, Germany) consisting of a binary pump, an autosampler and a 
temperature controlled column department at 65°C with a Waters (Milford, MA, USA) acquity 
UPLC BEH amide 1.7 µM 3.0x100 mm HILIC column coupled to a Q-TOF II mass 
spectrometer with an electrospray ionization source and liquid chromatography sprayer from 
Bruker Daltonics (Bremen, HB, Germany), operated in positive mode. The compounds were 
eluted isocratically with 40% water containing 300 µM formic acid and 550 µM NH4OH (pH 
9.2) and 60% acetonitrile (% v/v) at a flow rate of 0.6 mL/min. The injection volume was 20 µL. 
MS settings were optimized for MNA signal-to-noise ratio. The optimal settings were a capillary 
voltage of 1500 V, a nebulizer pressure of 4.1 bar, a drying gas flow rate of 9.8 L/min, a drying 
temperature of 220 °C, a scan range of m/z 90-400 and a spectra sample rate of 3 spectra/s.  
Analytical Method Validation  
The MNA analysis was validated between 0.31-100 µM for within and between run accuracy 
and precision, linearity of calibration curve, sample recovery and limit of detection. For the other 
substrates a system suitability test was performed, consisting of a linearity test and within run 
accuracy and precision test at the same concentration levels as for MNA. 
Linearity was performed with calibration points consisting of 0.31, 0.62, 1.25, 2.5, 5, 10, 25, 
50 and 100 µM MNA in water. Quality control (QC) samples consisted of 50 mM Tris Buffer, 1 
mM DTT and 16.25 µg/mL (550 nM) NNMT, and MNA concentrations of 0.31, 10 and 100 µM 
(all final concentrations). Samples for analysis were worked-up as described above in the 
enzymatic activity assay section and analysed with the optimized UHP-HILIC-MS method. 
Ratios of MNA and internal standard d3-MNA were calculated and plotted against the 
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concentration. Linearity was assessed visually and by calculation of Pearson’s r, which should be 
>0.95. Sample recovery was calculated by analysing a treated QC sample with UHP-HILIC-MS 
and by comparing this signal with the signal obtained by the analysis of an untreated sample in 
acetonitrile:water (80:20%, v/v) with the same concentration. The sample recovery was 77±2% 
and 83±4% for MNA and d3-MNA, respectively (n=8). All accuracy and precision results were 
within the pre-set limits of 85-115% for accuracy and <15% for precision (Table 1). 
The accuracy was tested by analysing the QC-samples using the complete method, including 
sample pre-treatment and by calculating the percentage of determined concentration with respect 
to the nominal value. The precision was defined as the coefficient of variation of the accuracy 
results. Accuracy and precision tests were performed in six-fold per concentration in 1 run and in 
one-fold per concentration in 3 separate runs. The acceptance criteria of the accuracy results 
were 85-115% and of the precision results <15%. The limit of detection was obtained by analysis 
of 8 pre-treated samples corresponding to a signal-to-noise ratio of 3 (Table 1). All other 
methylated substrates were analyzed with the same analytical method and a system suitability 
Table 1. Validation parameters of the UHP-HILIC-MS method for MNA 
QC conc. (µM) Pearson’s r  
0.31 - 100 0.996 – 0.998  
 Accuracy (%) Precision CV (%) 
Within run (n=6)   
0.31 87.5 2.9 
10 100.5 3.6 
100 86.9 2.1 
Between runs (n=3)   
0.31 85.3 4.7 
10 104.8 3.6 
100 88.0 0.8 
Limit of detection (S/N ≥ 3) 0.16 µM  
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test performed prior to analysis. This test involved confirming calibration curve linearity as 
described for MNA and an accuracy determination by analysis of QC samples at concentrations 
of 0.31, 10, and 100 µM. The calibration curves were found to be linear from 0.31-100 µM and 
within-run accuracies and precisions were within the 85-115% range and <15%, respectively. 
Data Analysis 
The data obtained from the UHP-HILIC-MS system included a linearity line with ten different 
concentrations of reference standard (from 0.16-100 µM) and a fixed concentration of internal 
standard (10 µM). These data-points were subjected to weighted regression (1/x2). The intercept 
and slope were used for determination of the measured concentrations. 
For quantification of the methylated product, the ratio of analyte to internal standard was 
calculated by integrating the corresponding peak areas in the chromatogram of test samples. The 
ratio was quantified using the linearity line obtained with the reference standards. The 
concentrations were then converted to enzyme velocity in nmoles produced/hour/mg hNNMT 
protein using equation 1 with the concentration of the methylated product in nM, time in 
minutes, and the enzyme concentration in mg/L. 
𝑣 = !"#$%&' ∗!"!!    Equation [1] 
 
Calculation of Vmax and KM was done using Graphpad Prism 6 following non-linear 
(Michaelis-Menten) regression analyses using equation 2. 
𝑣 = !"#$. !!"![!]     Equation [2] 
 
 
11 
The kcat was calculated from the Vmax using equation 3 with Vmax in nmol/hour/mg enzyme 
and enzyme concentration in mg/L. To obtain kcat with the unit s-1, the maximum velocity Vmax is 
divided by 3600. 
 𝑘!"# = !!"#!     Equation [3] 
In cases where the product formation was fund to decrease at high concentration of 
substrate, the data was fitted to an expression accounting for substrate inhibition (equation 4). 
𝑣 = 𝑉!"# ∗ !!"! ! ∗ !! !!"    Equation [4] 
 
Inhibition assays 
The NNMT inhibitory activity of the general methyltransferase inhbitors AdoHcy and sinefungin 
was evaluated using the UHP-HILIC-MS method. In this assay the substrate concentrations used 
were set at values near their measured Km values (10 µM AdoMet and 200 µM nicotinamide). 
AdoHcy and sinefungin were applied at ten different concentrations between 10 nM and 5000 
µM, measured in duplicate. The inhibitors were first incubated with NNMT for 10 minutes at 
37°C, after which the reaction was initiated by addition of a mixture of nicotinamide and 
AdoMet. After a reaction time of 10 minutes at 37°C a 15 µL aliquot was taken and added to 70 
µL of acetonitrile (containing 10 µM d3-MNA as internal standard). Quantification of the MNA 
generated was achieved as described above. Blank samples (no enzyme) and positive controls 
(no inhibitor) were also performed. The percent activity values were plotted as a function of 
inhibitor concentration and fitted using non-linear regression analysis of the Sigmoidal dose–
response curve generated using normalized data and a variable slope following equation 5, 
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Y= !""(!!!"((!"#$%!"!!)∗!"##$#%&')))  [Equation [5] 
 
 
where Y = percent activity, X = the logarithmic concentration of the compound and Hill Slope = 
slope factor or Hill coefficient. The IC50 value was determined by the concentration resulting in a 
half-maximal percent activity. The standard errors of the mean (S.E.M.) were reported using the 
symmetrical CI function in Graphpad Prism 6. 
 
RESULTS AND DISCUSSION 
Analytical Method Development 
To achieve a rapid and efficient method for measuring the methylating activity of NNMT we 
employed an UHP-HILIC-MS approach to detect MNA and other methylated pyridine products 
of the enzymatic reaction. The method developed was optimized so as to achieve maximum 
detection sensitivity and sample throughput. In optimizing the UHP-HILIC aspect of the method 
we examined the influence of the mobile phase composition and pH, column temperature, and 
flow rate on the elution profile of a standard MNA sample. Initial attempts employed isocratic 
elution with a mobile phase consisting of 40% acetonitrile containing 50 µM formic acid (pH 
2.2) at a flow rate of 0.5 mL/min at 25°C. This method yielded broad and tailing 
chromatographic peaks for MNA. Increasing the amount of formic acid (up to 300 µM) 
improved peak shape and decreased retention time. As MNA is inherently positively charged, an 
acidic eluent is not essential to obtain sufficient MS response so we also investigated the use of 
alkaline mobile phases. An increase in eluent pH by addition of NH4OH decreased the 
background noise without affecting the peak area for MNA and considerably improved 
efficiency while further shortening retention time due to the higher salt concentration. Optimal 
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peak shape and retention time were obtained with an eluent containing 300 µM formic acid and 
550 µM NH4OH (pH 9.2). While these are relatively high concentrations of eluent additives for 
use in MS, we found that they did not lead to MNA signal suppression relative to the initial 
analyses performed using eluent containing 50 µM formic acid.  An increase in column 
temperature (up to 65°C) resulted in a lower back pressure caused by a lower solvent viscosity 
and an enhancement of efficiency due to an increase in mass transfer. The effect of flow rate was 
also studied within a range of 0.2-1.0 mL/min. As expected, the highest flow rate tested 
decreased retention time but had the additional effect of narrowing the MNA peak at baseline to 
just 4.5 seconds making it difficult to acquire enough data points to define peak shape. The 
amount of data points could be increased by raising the spectra acquisition rate of the MS 
instrument but this also negatively affected MS response. As a compromise, a flow rate of 0.6 
mL/min and an acquisition rate of 3 spectra/s were chosen to ensure at least 10 data points to 
define the peak and to obtain an acceptable retention time and MS response. With these 
optimized parameters a chromatogram of an MNA sample could be acquired every 2.0 min while 
assuring optimal chromatographic conditions (Figure 2). The analysis of other pyridine-based 
Figure 2. Representative UHP-HILIC-MS trace for the NNMT-catalysed methylation of nicotinamide. Indicated are: 
the total ion chromatogram of the assay mixture (grey dashed line) and the extracted ion chromatograms for 
nicotinamide (NA, m/z 123.1, black line), N-methylnicotinamide (MNA, m/z 137.1, red line) and N-
trideuteromethylnicotinamde (d3-MNA, m/z 140.1, blue line). 
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NNMT substrates was also successfully performed using the same approach showing the method 
to be generally applicable. 
Internal Standards 
In order to quantify formation of the methylated pyridine products for nicotinamide and all other 
pyridine substrates, trideuterated versions were employed as internal standards. The trideuterated 
species have the same retention time and behaviour as their non-deuterated versions but can be 
separated based on m/z difference and can thereby be used to correct for matrix effect, signal 
suppression, and other effects due to sample preparation. A rapid and reliable procedure for the 
synthesis of both the non-deuterated reference standards and the trideuterated internal standards 
was developed (Scheme 1). Reaction of the pyridine compounds with either CH3I or CD3I under 
microwave irradiation followed by a simple workup consisting of filtration and washing of 
precipitated product generally provided the methylated reference standards as their iodide salts in 
high purity. For two of the substituted pyridines identified as alternate NNMT substrates 
(thionicotinamide 5 and 2-methoxypyridine 10) this general procedure was not suitable and 
alternative syntheses of the methylated products were employed (see supporting information).  
N
NH2
O
N
NH2
O
N
NH2
O
H H D D
H D
MW = 140.1MW = 137.1
CH3I
CH3CN, µW, 
140oC, 1.5 hr
CD3I
CH3CN, µW, 
140oC, 1.5 hr
11b 1c
Scheme 1. General procedure used for the synthesis of reference 
standards (using methyl iodide), and internal standards (using 
trideuteromethyl iodide). 
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Analysis of NNMT activity and substrate tolerance 
We next examined the suitability of the UHP-HILIC-MS method in determining the kinetic 
parameters for the various NNMT substrates. To begin we first established the Km values for 
AdoMet and nicotinamide. For the Km determination of nicotinamide a fixed concentration of 40 
µM AdoMet was used with a range of nicotinamide concentrations from 0.02-50 mM. For the 
AdoMet Km determination a fixed concentration of 2 mM nicotinamide was employed with 
AdoMet concentrations ranging from 0.2-200 µM. Using this approach the Km value determined 
for nicotinamide was 199 µM and for AdoMet 8.5 µM (Figure 3). Both Km values are in good 
agreement with those previously reported by others using different assay methods for studying 
NNMT activity.4,21 
As described in the experimental section above, initial screens were also performed with a 
number of other pyridine-containing compounds (Figure 4) to identify alternative NNMT 
substrates. In cases where the preliminary screen revealed significant methylation activity 
(compounds 1-11), the initial velocity conditions for each substrate were established and the 
kinetic parameters Km, Vmax and kcat determined. Direct comparison of all substrates was done 
Figure 3. Michaelis-Menten curves for determination of the kinetic parameters of NNMT substrates nicotinamide and 
AdoMet. A) Concentration of nicotinamide varied (AdoMet 40µM fixed concentration) and B) Concentration of AdoMet 
varied (nicotinamde 2 mM fixed concentration). 
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based on the kcat/Km ratio of each substrate, a measure for the catalytic efficiency of an enzyme.22 
The kinetic parameters summarized in table 2 show that compounds 2 and 3 behave as effective 
NNMT substrates with catalytic efficiencies comparable to nicotinamide while those of 
compounds 6-11 are significantly lower. While compounds 12-17 were also confirmed as 
NNMT substrates, their much lower rates of methylation made it difficult to establish initial 
velocity conditions using our method and Km, Vmax and kcat values were therefore not determined. 
The data clearly demonstrates that the position of the amide moiety on the nicotinamide ring 
is crucial for activity as only minor methylation was observed for isonicotinamide 12 (less than 
2% relative to nicotinamide) and no methylation could be detected for picolinamide 18. Also, 
when the amide moiety is replaced with a carboxylic acid, the activity disappears completely as 
Figure 4. Substrates analysed for methylation by NNMT: A) Compounds 1-11 were confirmed as  
NNMT substrates with significant methylation activity. B) Compounds 12-17 were also found to be 
methylated but at a much lower extent. C) Compounds 18-27 showed no detectible methylation. 
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seen for compounds 19-21. Methylation was also not observed for quinolinic acid 22 and 
kynurenic acid 23. These findings can be explained by the presence of an aspartic acid residue in 
the active site (D197) that coordinates with the amide moiety of nicotinamide.13 It is likely that 
replacing the amide unit with a carboxylic acid group results in a repulsive interaction. A 
significant decrease in methylation was also observed for the nicotinamide analogues bearing a 
methyl ester (13) or N’-methylamide (14) replacement at position 3, again emphasizing the 
importance of the amide moiety in substrate recognition. Nicotinamide analogue bearing a 
thioamide (2), acetyl (8), or amidine (9) group at the 3-position were well tolerated. Simple 
pyridines containing either methyl (10) or methoxy (11) groups at the 2-position were also 
methylated albeit at a somewhat lower rate. Interestingly, no evidence of methylation was 
detected for pyridine (24) itself, tested as both the free-base and tosylate salt.  
In agreement with the findings of Alston and Abeles who studied the substrate scope of 
NNMT isolated from porcine liver,2 quinolines 4-7 were also found to be effective NNMT 
Table 2. Kinetic parameters of confirmed NNMT substrates ranked according to their relative catalytic efficiency 
# Substrate Km  (mM) 
Vmax  
(nmol/hour/mg) 
kcat 
(s-1) 
kcat / Km  
(s-1 mM-1) 
Relative  
kcat / KM 
1 Nicotinamide 0.199 ± 0.032 5942 ± 154 0.10157 0.5104 1.000 
2 Thionicotinamide 
0.111 ± 0.042 
1411 ± 181 0.03336 0.3005 0.589 
(Ki 6.6 ± 2.4) 
3 4-Methylnicotinamide 0.335 ± 0.058 5344 ± 158 0.09135 0.2727 0.534 
4 Isoquinoline 
0.087 ± 0.025 
1005 ± 75 0.01718 0.1975 0.387 
(Ki 20.2 ± 5.4) 
5 Quinoline 
0.609 ± 0.197 
2713 ± 398 0.04639 0.0762 0.149 
(Ki 10.2 ± 3.3) 
6 Tetrahydroisoquinoline 
0.613 ± 0.148 
1915 ± 254 0.04527 0.0739 0.145 (Ki 4.7 ± 1.2) 
7 Quinoline-3-carboxamide 0.364 ± 0.123 310 ± 44 0.00733 0.0201 0.039 
(Ki 9.7 ± 3.5) 
8 3-Acetylpyridine 0.727 ± 0.115 845 ± 25 0.01444 0.0199 0.039 
9 Nicotinimidamide 1.326 ± 0.280 790 ± 34 0.01350 0.0102 0.020 
10 2-Methylpyridine 2.029 ± 0.239 608 ± 16 0.01039 0.0051 0.010 
11 2-Methoxypyridine 0.548 ± 0.213 155 ± 11 0.00265 0.0048 0.010 
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substrates. Interestingly, methylation was also observed for the non-pyridine substrate 1,2,3,4-
tetrahydro-isoquinoline 6. These observations suggest that additional aromatic rings can be 
accommodated in the active site of the enzyme. The position of additional aromatic rings relative 
to the site of methylation also appears to be important as relatively weak methylation is observed 
for norharmane 15, bipyridine 16 and 4-phenylpyridine 17. Of particular note is a long-held 
interest in the metabolism of 17 given that its methylated product is a putative neurotoxin that 
has been implicated in causing Parkinson’s disease phenotypes.23 While the NNMT-mediated 
methylation of 17 has been proposed in the literature,23 our data is the first to show that it can in 
fact be methylated by NNMT in vitro. Unique among the different compounds evaluated as 
NNMT substrates are tetrahydroisoquinoline 6 and bipyridine 16 as both could, in principle, 
undergo two methylations. The data obtained for the incubation of these compounds with NNMT 
however, provided no signal indicative of the doubly methylated products. In addition to the 
relatively simple compounds discussed above, more complex pyridine compounds of biological 
relevance were also evaluated as NNMT substrates. To this end nicotine 24, chloroquine 26, and 
quinine 27 were tested but showed no methylation activity, presumably due to an inability to 
access the NNMT active site. 
Of note are the substrate inhibition kinetics observed for thionicotinamide 2 and quinolines 
4-7. Compounds 2 (Ki = 6.6 mM), 4 (Ki of 20.2 mM), 5 (Ki of 10.2 mM) 6 (Ki of 4.7 mM), and 7 
(Ki of 9.7 mM) all inhibit the enzyme when administered at high concentrations (see 
supplemental information section for inhibition curves). This data may point towards the 
presence of an allosteric binding site through which the activity of NNMT might be regulated. 
While the concentration of these compounds needed to cause inhibition may not be 
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physiologically relevant, the results provide new insight into the possibility of inhibiting NNMT 
via interactions at alternate binding sites.  
Inhibition studies 
Among the various methods developed to date for studying NNMT activity, none have yet been 
applied towards characterizing NNMT inhibition. We therefore next evaluated the application of 
the UHP-HILIC-MS based method for assessing the inhibition of NNMT by two general and 
well-studied methyltransferase inhibitors, AdoHcy and sinefungin. Given their structural 
similarity with AdoMet these compounds are capable of inhibiting a wide range of AdoMet-
dependent methyltransferases (Figure 5).  
The UHP-HILIC-MS assay conditions were modified to achieve optimal results for 
inhibition screening rather than activity screening. For the assay used in studying NNMT activity 
with various substrates the cofactor AdoMet was employed at saturating conditions. For studying 
NNMT inhibitors that are competitive for AdoMet and/or nicotinamide binding, however, it is 
important that both substrates be used at concentrations near their Km values so as to achieve 
reliable inhibition data.24 The concentrations of AdoMet and nicotinamide were therefore set at 
10 µM and 200 µM respectively. For the purposes of generating IC50 curves for AdoHcy and 
sinefungin the inhibitors were incubated with NNMT over a concentration range of 10 nM to 
Figure 5. The structures of cofactor AdoMet and general methyltransferase inhibitors AdoHcy 
and sinefungin 
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5000 µM. The enzyme reaction was initiated by addition of nicotinamide/AdoMet mixture and 
left to react for 10 minutes prior to sampling for analysis. Based upon the residual NNMT 
activity measured, inhibition curves were generated giving IC50 values of 26.3 ± 4.4 mM and 3.9 
± 0.3 mM for AdoHcy and sinefungin respectively (Figure 6). These findings demonstrate the 
utility of the UHP-HILIC-MS assay here developed for obtaining detailed NNMT inhibition 
data. 
 
CONCLUSION  
We here describe the development of a rapid and convenient analytical method for measuring the 
activity of NNMT based on the use of an UHP-HILIC-MS approach. The method can be reliably 
used for the detection and quantification of NMA as well as a range of other positively charged, 
methylated pyridines. This assay represents a significant improvement over existing methods 
used for studying the activity of NNMT and specifically benefits from run-times of a little as two 
minutes, convenient sample preparation, high sensitivity, and the use of readily synthesized 
deuterated internal standards. 
Figure 6. IC50 curves for A) AdoHcy and B) Sinefungin based on 10 different concentrations measured in duplicate 
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The broad applicability of the method was also demonstrated by studying the NNMT-
mediated methylation of a wide range of substituted pyridines. In doing so, the kinetic 
parameters Km, Vmax and kcat where determined for a number of alternate NNMT substrates. The 
results provide insight into the methylating abilities of NNMT in vitro along with detailed 
information on the relative catalytic efficiency for each substrate. From the data obtained it is 
clear that NNMT can accommodate a relatively wide variety of pyridine-containing small 
molecules. Whether methylation of such alternate NNMT substrates is relevant in vivo is unclear 
given that they would also have to compete with nicotinamide. However, given that cellular 
nicotinamide levels can fluctuate significantly (depending, for example, on dietary intake) the 
likelihood of alternate substrates being methylated by NNMT may also vary accordingly. 
We here also demonstrated the applicability of the UHP-HILIC-MS method for assessing 
the inhibitory effects of small-molecule NNMT inhibitors. To date, none of the other NNMT 
assays developed have been shown to be applicable in providing detailed inhibition data. We 
found our method to be readily adaptable in generating NNMT inhibition curves and IC50 values 
for the known methyltransferase inhibitors AdoHcy and sinefungin. Given the increased interest 
in NNMT as a therapeutic target it is likely that the method here described will be of great value 
in identifying new NNMT inhibitors. Importantly, the rapid and convenient nature of the assay 
should also lend itself to the screening of inhibitor libraries. In this regard investigations are 
currently underway in our group aimed at developing novel NNMT-selective inhibitors, the 
results of which will be presented in due course. 
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